Table 1.
Characteristics of selected second-generation CAR products studied in B-cell lymphomas.
| Axicabtagene ciloleucel | Tisagenlecleucel | Lisocabtagene maraleucel | |
|---|---|---|---|
| US FDA indication for lymphoma | Adult DLBCL | Adult DLBCL | Not applicable** |
| Costimulatory domain | CD28 | 4-1BB (CD 137) | 4-1BB (CD 137) |
| scFv | FMC63 | FMC63 | FMC63 |
| Vector delivery | Retrovirus | Lentivirus | Lentivirus |
| Defined cells | No | No | Yes, CD4:CD8 fixed ratio |
| Lymphodepleting chemotherapy (×3 days) |
Cy 500 mg/m2
Flu 30 mg/m2 |
Cy 250 mg/m2
Flu 25 mg/m2* |
Cy 300 mg/m2
Flu 30 mg/m2 |
*
An alternate lymphodepletion regimen can be given prior to tisagenlecleucel consisting of: bendamustine 90 mg/m2 IV daily for 2 days if a patient previously experienced grade 4 hemorrhagic cystitis or demonstrates resistance to a previous Cy-containing regimen.
**
Lisocabtagene maraleucel is not approved for commercial use at the present time.
CAR, chimeric antigen receptor; Cy, cyclophosphamide; DLBCL, diffuse large B-cell lymphoma; FDA, US Food and Drug Administration; Flu, fludarabine; IV, intravenous; scFv, single-chain variable fragment.